Literature DB >> 1536412

Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline 2. Serum albumin concentration and incidences of pulmonary oedema and acute renal failure.

M A Stockwell1, A Scott, A Day, B Riley, N Soni.   

Abstract

All patients admitted to an Intensive Care Unit were assigned randomly to one of two groups, A and B. Group A received colloid volume replacement as 4.5% albumin whilst group B received a synthetic colloid, polygeline. This study describes the changes in serum albumin concentration in survivors and nonsurvivors in the two groups during their stay in the Intensive Care Unit. The incidences of renal failure and pulmonary oedema were also assessed. Serum albumin concentration decreased in all nonsurvivors. In survivors the serum albumin concentration decreased to a greater extent in the synthetic colloid group than in the albumin group. Despite the differences in serum albumin concentration there were no significant differences between the groups in the incidences of pulmonary oedema or renal failure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536412     DOI: 10.1111/j.1365-2044.1992.tb01942.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  13 in total

1.  Clinical practice guidelines for the use of albumin: results of a drug use evaluation in a Paris hospital. Tenon Hospital Paris.

Authors:  I Debrix; D Combeau; F Stephan; A Benomar; A Becker
Journal:  Pharm World Sci       Date:  1999-02

Review 2.  Exploding the albumin myth.

Authors:  M M Tjoeng; A K Bartelink; L G Thijs
Journal:  Pharm World Sci       Date:  1999-02

Review 3.  Adjunctive drug treatment in severe hypoxic respiratory failure.

Authors:  S Elsasser; H Schächinger; W Strobel
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 4.  Colloid solutions for fluid resuscitation.

Authors:  Frances Bunn; Daksha Trivedi
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  Safety of gelatin for volume resuscitation--a systematic review and meta-analysis.

Authors:  D O Thomas-Rueddel; V Vlasakov; K Reinhart; R Jaeschke; H Rueddel; R Hutagalung; A Stacke; C S Hartog
Journal:  Intensive Care Med       Date:  2012-04-18       Impact factor: 17.440

Review 6.  Colloid solutions: a clinical update.

Authors:  Tomi T Niemi; Ryo Miyashita; Michiaki Yamakage
Journal:  J Anesth       Date:  2010-10-17       Impact factor: 2.078

Review 7.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

8.  Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients.

Authors:  Franziska Schabinski; Janaina Oishi; Fabio Tuche; Alain Luy; Yasser Sakr; Donald Bredle; Christiane Hartog; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

Review 9.  Debate: Albumin administration should be avoided in the critically ill.

Authors:  T B Pulimood; G R Park
Journal:  Crit Care       Date:  2000       Impact factor: 9.097

10.  Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial : GENIUS-Gelatine use in ICU and sepsis.

Authors:  Gernot Marx; Kai Zacharowski; Carole Ichai; Karim Asehnoune; Vladimír Černý; Rolf Dembinski; Ricard Ferrer Roca; Dietmar Fries; Zsolt Molnar; Peter Rosenberger; Manuel Sanchez-Sanchez; Tobias Schürholz; Tamara Dehnhardt; Sonja Schmier; Elke von Kleist; Ute Brauer; Tim-Philipp Simon
Journal:  Trials       Date:  2021-06-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.